BRIEF—Aspire in-licenses Retinolx from Orphanix

Anglo-American firm Aspire Pharma has in-licensed Retinolx (vitamin A) from Orphanix, an Austrian biopharma focussed on the development of novel therapeutic orphan drugs across a range of pediatric therapy areas.

Retinolx brings Aspire a therapeutic candidate in bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in pre-term infants. It allows the option for both intramuscular and intravesical administration.

Richard Condon, chief executive of Aspire, said: “This acquisition demonstrates our commitment to advance the science and treatment options for orphan drug designations in vulnerable patient groups. Through our in-house expertise and network of global leaders in these respective fields, we strive to bring breakthrough advances in clinical management.”

Financial terms of the deal have not been disclosed.